At 43, Sandra*, a media attorney in Los Angeles, has contemplated breast enhancement since her twenties; however, she was deterred by the procedural pain, extended recovery period, and the notion of having a “foreign object” in her body.
Last summer, when Sandra, who wished to remain anonymous for confidentiality, learned about a novel injectable body contouring option, she felt curious. It promised no synthetic fillers, no implants, and no recovery time.
“Reaching a certain age prompts you to decide to do something just for yourself,” she remarked. The product she discovered, alloClae—pronounced similarly to the clay used for sculpting—is quick to administer. Dubbed the lunchtime breast enhancement, it typically requires less than an hour for injection, without the need for general anesthesia or a clinical environment. Furthermore, Sandra noted that the aftercare was “surprisingly simple.” The use of fat sourced from donated cadavers didn’t deter her. “I was perfectly okay with that,” she stated.
An increasing number of individuals in the United States seem to share her sentiment. Since May 2025, over 2,000 patients have been treated with alloClae, according to Tiger Aesthetics, the company behind the product. Discussions about it are gaining traction on Reddit’s popular plastic surgery forum, where potential clients inquire, share experiences, and exchange referrals for practitioners.
In 2026, it’s evident that what used to be considered body modification is now simply regarded as body maintenance. Altering one’s physical appearance has become more accessible and commonplace. Procedures like rib remodeling, upper and lower blepharoplasty, mid and lower facelifts, and deep-plane facelifts are increasingly sought after as advancements in technology and surgical methods continue to evolve, mirroring our desire for new curves, firmer skin, and defined jawlines.
AlloClae serves as a notable example of innovation in this field. However, while some plastic surgery clinics tout it as a “next-generation” innovation, others label it “zombie filler” or “corpse injections.”
If there exists a limit in the quest for an ideal appearance, are we nearing it? What does societal acceptance of cadaver fat injections signify for beauty standards? Could alloClae achieve the same ubiquity as Botox?
Ultimately, your perspective on alloClae may hinge on your views about mortality.
The Ozempic Effect
In 2024, alloClae was initially introduced in the US to board-certified plastic surgeons experienced in fat procedures, and starting in January, it was made available to a broader range of medical professionals, including mid-level providers such as physician assistants, nurse practitioners, and aesthetic nurses. (Tiger Aesthetics mentioned that they offer specialized training to nurse practitioners, who are restricted from injecting into the breast.)
Dr. Luis Macias, a double-board-certified plastic surgeon in Los Angeles, was among the first to use alloClae and has seen its popularity surge. “I find myself ordering syringes in bulk and constantly communicating with the representative about it,” he shared during a phone conversation. “It feels like I’m negotiating with my Porsche dealer… It’s absurd.” Each 12.5cc syringe of this soft tissue enhancer can cost up to approximately $2,250.
Marketed as “off-the-shelf” fat or “bottled fat grafting,” as one press release described it, alloClae is presented as an alternative to autologous fat grafting, which involves extracting a patient’s own fat via liposuction and relocating it to another area.
This isn’t the first injectable of its kind. Renuva, another shelf-stable cadaver fat injectable produced by the non-profit organization MTF Biologics, was released about ten years ago. According to Macias, the main difference is in volume; Renuva’s maximum syringe size is only 3cc, making it suitable for smaller areas like the face, hands, and neck. In contrast, the largest alloClae syringe can contain approximately 22cc. “It’s a bit chunkier,” Macias explained. “And somewhat firmer.”
In a time when GLP-1 medications are causing body sizes to shrink, the availability of donated cadaver fat is filling a niche in the market. Approximately 11% of Americans are currently using weight loss medications such as Ozempic and Wegovy, according to a recent report. Macias noted that many of his patients who are on GLP-1s are eager to restore fat to specific areas where they’ve lost volume, allowing them to reshape their silhouettes. “They want it back in the breasts, buttocks, and face,” he remarked. “These are common areas we’re targeting for re-volumization after excess skin removal.”
Caroline Van Hove, president of Tiger Aesthetics, concurred that the surge in these medications has complemented the demand for alloClae. “Patients are discovering that significant weight loss can result in specific areas losing volume, leading to a disfigured appearance,” she explained via Zoom. “In areas that they feel define their femininity.”
To accommodate the increasing demand, Van Hove mentioned that the company is expanding production, which poses challenges for a business reliant on cadaver donations. Macias indicated that he hasn’t encountered any patient expressing discomfort regarding the source of the fat. “Perhaps it’s due to the clientele I serve,” he reflected. “It is Los Angeles, after all.”
Ethical Considerations of Cadaver Use
Are families and donors aware that their bodies may be utilized in this manner? The short answer is that this is not always the case.
Organ and whole-body donations are often perceived as the ultimate selfless contributions—families leveraging their loss to enhance someone else’s life or advance scientific knowledge.
Organ donation is relatively straightforward—regulated stringently by federal law in the US. However, the landscape for whole body donations and non-transplant human tissue banks is quite different. Regulations differ by state, and there is currently no federal accreditation or licensing requirements for body donation organizations or non-transplant tissue banks, which the US Food and Drug Administration does not oversee. This results in a lack of federal oversight for the hundreds of facilities that receive tens of thousands of donated bodies annually.
Nevertheless, Van Hove described whole-body donation as a “stringent and highly regulated field.” She indicated that Tiger Aesthetics only collaborates with tissue banks associated with the Association for Advancing Tissue and Biologics—a voluntary accrediting organization formed in 1976 to enhance public trust through increased scrutiny of the donation process. Donors “must complete a comprehensive dossier granting their consents,” Van Hove detailed, noting that it can take between three to six months to review a donor’s medical history and approve the anatomical donation. “Naturally, the form does not specify ‘Do you wish to donate your organs or tissue to alloClae?’” she clarified. “However, it allows donors to indicate whether they want their donation exclusively for research purposes, medical studies, for profit, or if they have no restrictions at all.”
The ethical implications of this practice remain open for debate, particularly since donor families do not receive compensation for their loved ones’ bodies. “Profiting from altruism poses a significant ethical dilemma,” stated Arthur Caplan, a bioethics professor at NYU’s Grossman School of Medicine, during a video call. “This raises an ethics issue.”
Regarding increased production, Tiger Aesthetics informed USdaily that they are collaborating with additional tissue banks across the US to secure more cadavers and are looking to expand the age eligibility criteria for donors. However, their attempts to scale were somewhat hindered this summer when the New York State Health Department rejected the product’s distribution. New York is among the few states that mandate non-transplant tissue banks and entities involved in distributing, processing, storing, or collecting human tissue to possess a license. Recent court documents reveal that in October 2024, the Department of Health denied a license to alloClae’s manufacturers due to doubts about its “compliance with FDA standards” and again in May 2026, asserting that “the tissue bank owners, controlling parties, medical director, or tissue bank director lack the character and competence necessary for proper operation in accordance with the law.” Tiger Aesthetics, which asserts that its product is “regulated in compliance with the law” by the FDA, has initiated legal proceedings against the Department of Health, arguing it does not possess the authority to obstruct the product’s distribution. The company is pursuing at least $500,000 in damages for lost revenue and seeks a court ruling declaring that the “New York Tissue Bank regulatory framework does not pertain to adipose tissue-derived products” like alloClae, among other requests for relief.
‘Oily, Chunky, and Yellow’
When discussing cadaver fat, patient Jackelin Cruz, who received treatment from Macias, admitted she initially found the concept “slightly odd.” However, she felt reassured knowing that the donor’s DNA is removed during the manufacturing process, as stated by Tiger Aesthetics.
Cruz, a 60-year-old homemaker from Los Angeles, was at Macias’ clinic for her routine Botox and laser session when she noticed a pamphlet for alloClae. She had contemplated enhancing her buttocks—sometimes feeling self-conscious even in front of her husband and opting to tie a sweater around her waist—but Macias informed her that she was too slim for a traditional Brazilian butt lift (BBL). Even if she had enough fat reserves, Cruz was apprehensive about the recovery from such surgery. Ultimately, she favored alloClae due to its minimal downtime and the option to gradually enhance her desired shape over several sessions. In total, she underwent two treatments, which cost nearly $50,000 combined. She was thrilled with her alloClae results and is now considering using it on other areas of her body.
Meanwhile, Sandra invested $13,000 for 50cc of alloClae in each breast, considering it a fair price thanks to a volume discount from her surgeon. Unfortunately, she experienced complications. About two months after her breast enhancement, Sandra reported pain in her right side, with her skin turning yellow-brown and purple, resembling a bruise. She felt lumps in her breast and was eventually diagnosed with fat necrosis by her surgeon. The injected fat failed to vascularize—where new blood vessels develop and enhance blood flow to the area—and began to die within her body. One day after showering, Sandra noticed yellow fluid leaking from the injection site on her right breast. “It looked remarkably like the alloClae,” she remarked. “It was oily, chunky, and yellow.”
Van Hove stated that Tiger Aesthetics has not confirmed any incidents of graft rejection or alloClae-related infections. She refrained from commenting specifically on Sandra’s experience, which would have been managed by the company’s quality assurance team, but emphasized that injection “technique is critical.”
Both Van Hove and Dr. Krishna Vyas, a New York-based plastic surgeon, noted that standard fat grafting using a patient’s own fat also carries a risk of necrosis, though further evaluation is challenging due to the lack of direct comparison studies between the two methods. While Vyas described the product as “low risk,” he expressed hesitation about employing it in his practice until more comprehensive clinical trials with long-term follow-up data are available.
Although Sandra’s cysts were successfully aspirated, she mentioned she can still feel some lumps in her chest and was ironically advised that she might require surgery to remove any remaining alloClae.
The New Botox?
When Dr. Macias first started working with Renuva and alloClae, he braced for the anticipated horror surrounding the idea of “injecting deceased individuals’ fat into living patients.”
“Surprisingly,” he noted, “I haven’t had to provide much explanation.”
Cultural critic Arabelle Sicardi described alloClae as “horrifically convenient,” comparing it to elements found in Coralie Fargeat’s 2024 horror film, “The Substance.”
Sicardi suggested that the absence of recovery time contributes to a cognitive dissonance regarding the product’s components. “It implies that we prioritize convenience with materials sourced from the deceased,” Sicardi remarked. “This reflects a modern iteration of an age-old practice. People once consumed human remains; now we are incorporating them into our bodies.”
Nevertheless, Van Hove is optimistic about the injectable’s future. With her extensive experience in the medical aesthetics realm, she is well-positioned for this expectation. Having contributed to the launch of iconic products like Botox and Juvéderm, she stated, “Fillers, Botox, lasers, and needling—all these procedures were once considered radical due to their novelty. I believe they should be viewed as tools that enhance mental wellness and self-esteem.”
Rather than symbolizing human demise, she perceives alloClae as a form of rejuvenation. “Individuals are searching for ways to not only extend their lifespan but also to look and feel their best as they do so,” Van Hove expressed.
“Why strive to prolong life if your exterior doesn’t reflect the youthful spirit you’ve worked to maintain?”
